Angle Share News (AGL)
AGL Share
AGL Share
AGL Share
AGL Share
AGL
AGL Share
AGL Level 2
AGL Live
AGL Broker
AGL Directors
AGL Financial
AGL
AGL Short
AGL
Last checked at -
Angle, a specialist medtech company, has placed 4.53m new ordinary shares at 50p each, representing a discount of 17.4 per cent on the mid-price of 60.50p per share at close of business on Wednesday. Net of costs, the placing raised £2.2m, which will be used to strengthen the company's financial p
Read moreMedical technology firm Angle saw its shares jump for a second day in a row after it received cash due from the sale of its portfolio company Acoylte Biomedica. The 2007 sale led to a legal case over an earn-out provision, which saw former Acolyte shareholder, Porton Capital, take the buyer, 3M, to
Read moreAngle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix. The AIM listed company said it had edged further in the development of Parsortix, a non-invasive technology which captures and counts rare circulating tu
Read moreAIM-listed medtech company Angle revealed that Origio, a partner involved in the development of a technology patented as EmbryoSure, has decided to cease EmbryoSure studies in a business update on Monday. EmbryoSure is a technology being developed to assess the viability of embryos for transfer in
Read moreCyan Holdings, the wireless solutions company, has revealed that three more Cyan partners have received requests from the Tamil Nadu Electricity Board (TNEB) Automatic Meter Reading tender to proceed with installation and commissioning of 500 unit pilots within the next 25 days. The news follows Cya
Read moreDefence technology firm Westminster Group said its investment in a West African airport was looking promising and that an initial aggregate $150m revenue forecast could be achieved by the contract's eight year break point rather than the full contract term of 15 years. "Should that be the case, the
Read moreIntandem Films, the London and Los Angeles based international film group, will co-produce 10 Things I Hate About Life, and sell the film internationally. The company will also distribute the film in the UK. The script has been written and the film will be directed by Gil Junger, the director of the
Read moreShares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone. The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening techniqu
Read moreTop Level Domain Holdings, which operates generic top-level domains, has revealed that is wholly-owned subsidiary, Minds and Machines, has been appointed by Dot London Domains (DLD), the official promotional organisation for London, to assist with DLD's application for the position of registry opera
Read moreHMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in
Read moreTechnology investment company ANGLE has raised £1.2m through a fundraising on the same that it revealed it had swung to a loss in the first half ended October 31st. The firm said on Thursday that investors will acquire up to 1,715,717 new ordinary shares in the company at a price of 70p per shar
Read moreAngle's 90%-owned portfolio company, Parsortix, which specialises in medical diagnostics, has used its cell separation device to successfully capture circulating tumour cells (CTCs) in cancer patient blood. The Parsortix separation technology has already been used to capture cultured breast cancer
Read moreAngle, the technology investment company, saw its share price go vertical on Friday morning on the back of success at one its investments, Parsortix. Parsortix, which specialises in medical diagnostics, has confirmed its cell separation device can "capture cultured lung cancer cells". This comes af
Read moreShares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure. The embryo viability product is being developed by Novocellus, which is 82% owned by Angle. The firm had already said the trial of EmbryoSure was delayed, but today adde
Read moreAngle, the Surrey-based technology investment firm, has seen its share price rocket nearly 15% on news one of its divisions has found a new way to detect prostate cancer. Parsortix, which is 90% owned by Angle, claims its "separation technology" can capture prostate cancer cells added to blood. T
Read more
Last checked at